Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.

Kessous R, Octeau D, Klein K, Tonin PN, Greenwood CMT, Pelmus M, Laskov I, Kogan L, Salvador S, Lau S, Yasmeen A, Gotlieb WH.

Gynecol Oncol. 2018 Mar;148(3):553-558. doi: 10.1016/j.ygyno.2018.01.017. Epub 2018 Feb 1.

PMID:
29395310
2.

Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.

Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA, Welcsh P.

Mol Cancer. 2009 Jul 14;8:48. doi: 10.1186/1476-4598-8-48.

3.

Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.

Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W.

JAMA Oncol. 2015 Jul;1(4):486-94. doi: 10.1001/jamaoncol.2015.1432.

5.

External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.

Lee JY, Chung YS, Na K, Kim HM, Park CK, Nam EJ, Kim S, Kim SW, Kim YT, Kim HS.

J Gynecol Oncol. 2017 Nov;28(6):e73. doi: 10.3802/jgo.2017.28.e73. Epub 2017 Jul 24.

6.

Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?

Sioulas VD, Schiavone MB, Kadouri D, Zivanovic O, Roche KL, O'Cearbhaill R, Abu-Rustum NR, Levine DA, Sonoda Y, Gardner GJ, Leitao MM Jr, Chi DS.

Gynecol Oncol. 2017 Apr;145(1):15-20. doi: 10.1016/j.ygyno.2017.02.023. Epub 2017 Feb 21.

7.

Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.

Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, Eriksson AG, Gardner GJ, Sonoda Y, Levine DA, Aghajanian C, Chi DS, Abu-Rustum NR, Zivanovic O.

Gynecol Oncol. 2016 Mar;140(3):436-42. doi: 10.1016/j.ygyno.2016.01.008. Epub 2016 Jan 9.

8.

Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.

Mendiola M, Redondo A, Heredia-Soto V, Herranz J, Berjón A, Hernández A, Miguel-Martín M, Crespo R, Barriuso J, Cruz P, Yébenes L, Peláez-García A, Castelo B, DE Molina AR, Feliu J, Hardisson D.

Anticancer Res. 2018 Sep;38(9):5393-5400. doi: 10.21873/anticanres.12869.

PMID:
30194194
9.

A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.

Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH.

Gynecol Oncol. 2017 Aug;146(2):399-404. doi: 10.1016/j.ygyno.2017.05.037. Epub 2017 Jun 10.

10.

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA.

Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6.

PMID:
28273485
11.

Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.

Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K; BGI Group.

J Gynecol Oncol. 2017 Jul;28(4):e39. doi: 10.3802/jgo.2017.28.e39.

12.

BRCAness profile of sporadic ovarian cancer predicts disease recurrence.

Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, Skrepnik T, Wright J, Pande N, Hoatlin M, Pejovic T.

PLoS One. 2012;7(1):e30042. doi: 10.1371/journal.pone.0030042. Epub 2012 Jan 11.

13.

Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.

Rebbeck TR, Mitra N, Domchek SM, Wan F, Chuai S, Friebel TM, Panossian S, Spurdle A, Chenevix-Trench G; kConFab, Singer CF, Pfeiler G, Neuhausen SL, Lynch HT, Garber JE, Weitzel JN, Isaacs C, Couch F, Narod SA, Rubinstein WS, Tomlinson GE, Ganz PA, Olopade OI, Tung N, Blum JL, Greenberg R, Nathanson KL, Daly MB.

Cancer Res. 2009 Jul 15;69(14):5801-10. doi: 10.1158/0008-5472.CAN-09-0625. Epub 2009 Jul 7.

14.

Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.

Sokolenko AP, Savonevich EL, Ivantsov AO, Raskin GA, Kuligina ES, Gorodnova TV, Preobrazhenskaya EV, Kleshchov MA, Tiurin VI, Mukhina MS, Kotiv KB, Shulga AV, Kuznetsov SG, Berlev IV, Imyanitov EN.

Cancer Lett. 2017 Jul 1;397:127-132. doi: 10.1016/j.canlet.2017.03.036. Epub 2017 Apr 1.

PMID:
28377179
15.

Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.

Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM.

Genome Med. 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x.

16.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.

Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. Lancet Oncol. 2015 Feb;16(2):e55.

PMID:
25481791
17.

Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.

Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R.

Clin Cancer Res. 2005 Dec 1;11(23):8372-83.

18.

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.

Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.

Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21.

19.

Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.

Krivokuca A, Boljevic I, Jovandic S, Magic Z, Mandic A, Tomasevic Z, Brankovic-Magic M.

J Hum Genet. 2019 Apr;64(4):281-290. doi: 10.1038/s10038-019-0562-z. Epub 2019 Jan 16.

PMID:
30651582
20.

The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.

Ng CK, Cooke SL, Howe K, Newman S, Xian J, Temple J, Batty EM, Pole JC, Langdon SP, Edwards PA, Brenton JD.

J Pathol. 2012 Apr;226(5):703-12. doi: 10.1002/path.3980. Epub 2012 Feb 9.

PMID:
22183581

Supplemental Content

Support Center